Amgen Selling General Administrative History
| AMGN Stock | USD 344.55 -4.07 -1.17% |
Selling General Administrative | First Reported 1989-06-30 | Previous Quarter 1.7 B | Current Value 2 B | Quarterly Volatility 523.1 M |
Macro event markers
Latest Amgen Selling General Administrative Growth Pattern
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Selling General Administrative Trend Statistics
Amgen's Selling General Administrative carries a CV of 32.5% across 15 periods, indicating elevated dispersion relative to the mean. Linear regression yields an R-squared of 0.02, pointing to no statistically meaningful linear trend.| Arithmetic Mean | 4,251,595,940 | |
| Geometric Mean | 3,235,663,187 | |
| Coefficient Of Variation | 32.49 | |
| Mean Deviation | 883,559,151 | |
| Median | 4,573,000,000 | |
| Standard Deviation | 1,381,163,831 | |
| Sample Variance | 1907613.5T | |
| Range | 6.1B | |
| R-Value | 0.15 | |
| Mean Square Error | 1987581.9T | |
| R-Squared | 0.02 | |
| Significance | 0.56 | |
| Slope | 41,659,431 | |
| Total Sum of Squares | 30521816.5T |
Amgen Selling General Administrative History
Amgen reports Selling General Administrative from 2012 through 2026 across 15 observations, beginning at 4.8 B and ending at 2.8 B.| 2026 | 2.8 B | ||
| 2025 | 2.5 B | ||
| 2024 | 6.1 B | ||
| 2023 | 5.5 B | ||
| 2022 | 4.6 B | ||
| 2021 | 4.5 B | ||
| 2020 | 4.8 B | ||
| 2019 | 4.4 B | ||
| 2018 | 4.7 B | ||
| 2017 | 4.2 B | ||
| 2016 | 4.6 B | ||
| 2015 | 4.5 B | ||
| 2014 | 4.7 B | ||
| 2013 | 5.2 B | ||
| 2012 | 4.8 B |
Correlation of Selling General Administrative With Other Accounts
Cross-account correlations for Amgen's Selling General Administrative measure how closely related line items have moved together historically. Correlation does not establish cause and effect.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Sales General And Administrative To Revenue | 0.19 | 0.33 | |
| Price To Sales Ratio | 4.79 | 8.80 | |
| Dividend Yield | 2.91% | 1.94% | |
| PTB Ratio | 20.34 | 21.36 | |
| Days Sales Outstanding | 95.07 | 48.57 | |
| Book Value Per Share | 16.09 | 10.30 |
Methodology, Assumptions & Data Sources
The Selling General Administrative trend for Amgen is contextualized below with regression and dispersion statistics. Benchmarking this metric against sector peers distinguishes company-specific movement from industry-wide patterns. As a Biotechnology company, Amgen's Selling General Administrative should be benchmarked against sector peers for meaningful interpretation.
Amgen Inc values are built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Analyst projections are included when active coverage applies. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board